

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 June 2001 (21.06.2001)

PCT

(10) International Publication Number
WO 01/44506 A1

- (51) International Patent Classification⁷: **C12Q 1/68** (74) Agent: **CABINET GERMAIN & MAUREAU**; Boîte Postale 6153, F-69466 Lyon Cedex 06 (FR).
- (21) International Application Number: **PCT/IB99/02072**
- (22) International Filing Date:
17 December 1999 (17.12.1999)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicants (*for all designated States except US*): **BIO MERIEUX** [FR/FR]; Chemin de l'Orme, F-69280 Marcy L'Etoile (FR). **AFFYMETRIX INCORPORATED** [US/US]; 3380 Central Expressway, Santa Clara, CA 95051 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **LAAYOUN, Ali** [FR/FR]; Triangle Fleuri, 1, rue du Rhône, F-69007 Lyon (FR). **DO, Duc** [US/US]; 3206 Simberlan Drive, San Jose, CA 95148 (US). **MIYADA, Charles, Garret** [US/US]; 5151 Country Lane, San Jose, CA 95129 (US).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: PROCESS FOR LABELING A RIBONUCLEIC ACID, AND LABELED RNA FRAGMENTS WHICH ARE OBTAINED THEREBY

(57) Abstract: The present invention relates to a process for labeling with signal amplification a ribonucleic acid (RNA), characterized in that it comprises: fragmenting the RNA, fixing a first ligand to the terminal phosphate which is located at the 3' end and/or the 5' end of each fragment of said RNA, said terminal phosphate having been released during the fragmentation, and binding a labeling agent to said first ligand. The invention is preferably applied in the field of medical diagnosis.

WO 01/44506 A1

- 1 -

**Process for labeling a ribonucleic acid, and labeled RNA
fragments which are obtained thereby**

Field of the invention :

5 The present invention relates to a novel process
for labeling a ribonucleic acid (RNA) with signal
amplification.

Background of the invention :

10 The state of the art shows that there are a large
number of methods for labeling nucleotides,
oligonucleotides or nucleic acids; oligonucleotides and
nucleic acids will be referred to by the term
polynucleotides. Polynucleotides can be labeled either
15 during synthesis or by incorporating at least one labeled
nucleotide.

A first method comprises in attaching the label to
the base, whether the latter is a natural base or a
modified base. A second method proposes attaching the
20 label to the sugar, again whether the latter be a natural
sugar or a modified sugar. A third method relates to
attaching the label to the phosphate.

In fact, a person of skill in the art who is to
label a nucleotide or a nucleotide analogue or a nucleic
25 acid is inclined to attach the label to the base or to the
sugar, which offers him more convenience and more options.
This is, furthermore, what emerges from studying a large
number of documents such as EP-A-0.329.198,
EP-A-0.302.175, EP-A-0.097.373, EP-A-0.063.879,
30 US-A-5,449,767, US-A-5,328,824, WO-A-93/16094, DE-
A-3.910.151 and EP-A-0.567.841 in the case of the base or
EP-A-0.286.898 in the case of the sugar. Each of these

- 2 -

documents is hereby incorporated by reference for all purposes.

5 The technique of attaching the label to the phosphate is more complex especially because nucleic acids are water soluble and the reactivity of phosphate in this media is lower compared to that in organic solvents.

10 Even so, some documents have proposed techniques for labeling the phosphate. This applies, for example, to document EP-A-0.280.058, hereby incorporated by reference for all purposes, which describes labeling a nucleotide by attaching the label to the phosphate, with the latter being attached to the sugar in the 3' and/or 5' positions, when the nucleotide is a deoxyribonucleotide, and in the 2', 3' and/or 5' positions when the nucleotide is a
15 ribonucleotide. This document also describes a polynucleotide or oligonucleotide which comprises at least one labeled nucleotide as described above; this nucleotide is incorporated into the polynucleotide or oligonucleotide during synthesis.

20 However, the labeling strategy which is proposed by document EP-A-0.280.058 does not enable the nucleic acids to be labeled uniformly. The incorporation of the labeled nucleotides into the polynucleotides cannot be controlled; it depends entirely on the composition of
25 synthesized polynucleotides. Thus, some polynucleotides may contain a large number of labeled nucleotides whereas others may not contain any at all. As a result, the intensity of the signal emitted by these nucleic acids will not be uniform, and therefore it will be difficult
30 to interpret the results when detecting the nucleic acids.

- 3 -

In this case, the labeling is incorporated biologically without any control of the positions of the labeled nucleotides.

The document US-A-5,317,098 hereby incorporated by
5 reference for all purposes relates to nucleic acids which
are labeled at their 5' ends. This attachment uses
imidazole and a linker arm. There is no associated
fragmentation with the labeling. Furthermore, phosphate is
added to nucleic acids and therefore kinase is used as a
10 mean to introduce the phosphate, leading to at least one
additional biological step. This document describes the
labeling of a 15 mer oligonucleotide. When using large
nucleic acids instead of oligonucleotide, this technique
leads to the presence of a label only at the 5' end and
15 the specific activity of the labeled nucleic acid is low.

In addition, when the labeling is carried out on
large nucleic acids without a fragmentation stage, also
termed a cleavage stage, the kinetics of hybridization of
these labeled nucleic acids to their complementary
20 sequences, is slow leading to poor hybridization yield.
This will therefore result in a quantitative and
qualitative loss of the signal. Steric hindrance is a key
factor in this reaction.

Steric hindrance may not only be the result of the
25 length of the nucleic acid but also of the existence of
secondary structures. Fragmentation helps to broke (or
reduce) these structures and in this way to optimize
hybridization. Steric hindrance plays a particularly
important role in the case of hybridization to solid
30 surfaces which contain a high density of capture probes,
for example the DNA arrays developed by the company
Affymetrix, Inc. ("Accessing Genetic Information with

- 4 -

High-Density DNA arrays", M. Chee et al., Science, 274, 610-614, 1996. "Light-generated oligonucleotide arrays for rapid DNA sequence analysis", A. Caviani Pease et al., Proc. Natl. Acad. Sci. USA, 91, 5022-5026, 1994, US-
5 5 744 305, US-5 445 934). Each of these references is incorporated therein by reference for all purposes. In this technology, the capture probes are generally of reduced size, being of about twenty nucleotides in length.

A large number of methods are described in the
10 state of the art for fragmenting nucleic acids.

First, the fragmentation can be enzymatic, i.e. the nucleic acids can be fragmented by nucleases (DNases or RNases) (Methods in Enzymol., vol. 152, S. Berger and A. Kimmel, ed. Academic Press, 1987, Enzymatic techniques
15 and Recombinant DNA Technology, « Guide to Molecular cloning », p91-110, Molecular Cloning, a Laboratory Manual, J. Sambrook, E.F. Fritsch and T. Maniatis, Cold Spring Harbor Laboratory Press, 2nd Edition, p5.30-5.95, 1989). Each of these documents is hereby incorporated by
20 reference for all purposes.

Depending on the involved enzyme, this reaction generates small fragments or monomers having either a hydroxyl or a monophosphate group at their 5'-or 3'-ends.

Second, the fragmentation can be chemical. For
25 example, in the case of DNA sequences, the depurination or depyrimidination using alkylating agents generates abasic sites which are then fragmented in the presence of a base by a mechanism termed " β -elimination" (T. Lindahl et al., Rate of Chain breakage at apurinic sites in double-
30 stranded deoxyribonucleic acid., Biochemistry, 11, p3618-3623, 1972). The DNA's can be fragmented by oxidation, alkylation or free radical addition mechanisms, inter alia

- 5 -

(M. Liuzzi et al., Characterization and damage in gamma-irradiated and OsO₄-treated DNA using methoxyamine., Int. J. Radiat. Biol., 54, p709-722, 1988). Metal cations, which are often combined with organic molecules used as chemical catalysts, for example imidazole, are used for fragmenting RNA's. (R. Breslow and R. Xu, Recognition and catalysis in nucleic acid chemistry, Proc. Natl. Acad. Sci. USA, 90, p1201-1207, 1993. J. Hovinen et al. Imidazole Tethered Oligonucleotides : Synthesis and RNA cleaving activity, J. Org. Chem., 60, p2205-2209, 1995). This fragmentation is preferably carried out in an alkaline medium and generates fragments having 3'-phosphate ends. Each of these documents is hereby incorporated by reference for all purposes.

However, the objective of these fragmentations is not that of facilitating or permitting labeling.

Document WO-A-88/04300 proposes a method for fragmenting and labeling RNA, using RNA molecules which possesses enzymatic properties, i.e. ribozymes. Cleavage catalysis with these ribozymes is sequence specific and the reaction yields to RNA fragments having a hydroxyl group (OH) at their 5' end and a monophosphate at 3' end. The labeling, which is solely radioactive labeling, is then effected by incorporating an added radioactive phosphate which is derived from a molecule of GTP. It is a phosphotransferase activity of these ribozymes category, i.e. a kinase activity. The radioactive phosphate attachment is effected solely at the hydroxyl group at 5' end and no phosphate resulting from fragmentation is used for attaching the label to RNA fragments. Furthermore, the fragmentation is only carried out by ribozymes, implying the existence of a specificity between the

- 6 -

ribozymes and the target nucleic acids to be cleaved. The phosphate then acts as the label.

Our invention allows the label attachment to the phosphate of a nucleic acid fragment which is released
5 during the cleavage. There is no specificity and therefore, any type of nucleic acid can be fragmented in a random manner. The homogeneity of labeling intensity can be obtained using this approach since the labeling yield of each class of produced fragments is completely
10 independent on its sequence and composition. Thus, our process makes it possible to prepare detection probes, for example. Finally, the phosphate is only a linker arm between the nucleic acid and the label.

The technique of signal amplification is well known
15 in the field of immunoassays or nucleic acid probes as described for example in WO95/08000, or in the article J. Histochem. Cytochem. 45: 481-491, 1997 (each of which is incorporated by reference in its entirety for all purposes), but without fragmentation associated during the
20 labeling.

No process of fragmenting before labeling with signal amplification has been described in the prior art.

The present invention therefore proposes a process which overcomes the previously mentioned drawbacks. Thus,
25 this process makes it possible to obtain RNA fragments which are uniformly labeled once the fragmentation has been completed. In addition, the fragmentation makes it possible to obtain fragments which are of an optimum size for a possible hybridization. With the quality of the
30 hybridization having been improved, the post-hybridization detection of labeled fragments will be more rapid and efficient. Finally, the invention improves the sensitivity

- 7 -

by increasing the signal intensity produced and the ratio signal versus the background.

Summary of this invention :

- 5 To this end, the present invention relates to a process for labeling a synthetic or natural ribonucleic acid (RNA), characterized in that it comprises :
- fragmenting the RNA,
 - fixing a first ligand to the terminal phosphate which is
10 located at the 3' end and/or the 5' end of each fragment of said RNA, said terminal phosphate having been released during the fragmentation, and
 - binding a labeling agent to said first ligand.

15 Detailed description of the invention :

In the present invention, RNA (ribonucleic acid or polyribonucleic acid) is a synthetic or natural RNA.

Those of skill in the art will be familiar with methods of obtaining synthetic RNA. These methods include,
20 for example, amplification techniques (see, for example, Kozal M.J. and al, Nature Medicine, 2(7), 753-758, 1996, hereby incorporated by reference in its entirety for all purposes), transcriptional amplification techniques or other methods leading to RNA products including TMA
25 (Transcription Mediated Amplification), NASBA (Nucleic Acid Sequence-Based Amplification), 3SR (Self-Sustained Sequence Amplification), Q β replicase amplification, natural RNA digestion by enzymes, and polyribonucleotide chemical synthesis (see, for example, US Patent Nos
30 5,554,516 and 5,766,849 and Clin. Microbiol. Rev., 5(4), p.370-386, 1992 each of which is incorporated by reference in its entirety for all purposes. Synthetic RNA is also

- 8 -

RNA which comprises at least one modified nucleotide or at least one modified internucleotidic bond such as thiophosphate. A Natural RNA is a RNA which is obtained by extraction from a cell, for example a messenger RNA
5 (mRNA), a ribosomal RNA (rRNA) or a transfer RNA (tRNA).

Labeling is the attachment of a label which is able to generate a detectable signal. The following is a non-limiting list of these labels:

- enzymes which produce a detectable signal, for example
10 by colorimetry, fluorescence, luminescence, such as horseradish peroxidase, alkaline phosphatase, β -galactosidase and glucose-6-phosphate dehydro-genase,
- chromophores, such as fluorescent and luminescent compounds and dyes,
- 15 • groups having an electron density which can be detected by electron microscopy or by their electrical properties such as conductivity, amperometry, voltametry and impedance,
- detectable groups, for example whose molecules are of
20 sizes which are sufficient to induce detectable modifications in their physical and/or chemical characteristics; this detection can be effected by means of optical methods such as diffraction, surface plasmon resonance, surface variation and angle of contact
25 variation, or physical methods such as atomic force spectroscopy and the tunnel effect,
- radioactive molecules such as ^{32}P , ^{35}S or ^{125}I .

The compound which comprises the label is the labeling agent.

- 9 -

The term « fixing » means creating a covalent or a non covalent bond. An antibody selective of a phosphate or thiophosphate is a means to create a non covalent bond. According to a preferred mode of operation, the fixation
5 is covalent as described in the examples.

In one aspect of the present invention, the fragmentation and the fixation are effected in one step.

In another aspect of the present invention, the fragmentation and the fixation are effected in two steps.

10 According to a first embodiment, the binding of the labeling agent to the first ligand is covalent. The different reactive functions which allows the covalent coupling are well known to those of skill in the art and some examples of conjugation could be found for example in
15 « Bioconjugate techniques », Hermanson G.T., Academic Press, San Diego, 1996. Hereby incorporated by reference in its entirety for all purposes.

According to a second embodiment, the binding of the labeling agent to the first ligand is non covalent.
20 The non covalent binding is a binding involving, for examples, ionic or electrostatic interactions, Van der Waals' interactions, hydrogen bonds or a combination of different interactions.

In a preferred embodiment, the binding of the
25 labeling agent to said first ligand is effected indirectly. The first ligand, fixed to the terminal phosphate, is bound to a first antiligand, said first antiligand is bound to a second ligand and the labeling agent is a second antiligand bearing at least one label
30 and able to react with said second ligand.

-10-

The (antiligand/ligand) combination means two compounds which are able to react together in a specific manner.

First ligand / first antiligand and second ligand / second antiligand combinations are selected, for example, from the group consisting of biotin/streptavidin, hapten/antibody, antigen/antibody, peptide/antibody, sugar/lectin and polynucleotide/complementary polynucleotide.

These different combinations and other combinations are known and described for example in BioMerieux applications WO 96/19729, WO 94/29723, WO 95/08000 which are incorporated herein by reference.

The first and second ligands are the same or different.

In a preferred mode of operation, the first ligand is a derivative of fluorescein and the second ligand is a derivative of biotin.

In another preferred mode of operation, the first ligand is a derivative of biotin and the first antiligand is a derivative of streptavidin.

There is no limitation in stacking-up other entities (ligand / antiligand) to increase signal amplification. For example, a (second ligand / first antiligand) entity binds to the first ligand fixed to the phosphate, then a (third ligand / second antiligand) entity binds to the second ligand and the labeling agent is a third antiligand bearing at least one label and able to react with the third ligand.

The addition of different entities may be effected in at least one step or each entity may be added

-11-

successively after the fixation of the ligand to the phosphate.

According to a preferred mode of operation, the fixation of the first ligand to the 3' end of each
5 fragment of the RNA is effected apart from the fragment which constitutes the 3' and/or 5' end of the starting RNA. Additionally or alternatively, the fixation of first ligand to the 5' end of each fragment of the RNA is effected apart from the fragment which constitutes the 5'
10 end of the starting RNA.

Whatever the embodiment, fixation of the first ligand to the 3' end or the 5' end of an RNA fragment is effected by reacting a reactive function, which is carried out by the first ligand, to the phosphate which is in the
15 2' position, in the 3' position or in the cyclic monophosphate 2'-3' position, with respect to the ribose.

Fragmentation and/or the fixation of the first ligand to the 3' end or the 5' end of an RNA fragment is effected by binding a nucleophilic, electrophilic or
20 halide function which is carried by a ligand to the phosphate in the 2' position, in the 3' position or in the cyclic monophosphate 2'-3' position, with respect to the ribose.

Fragmentation of the RNA is effected
25 enzymatically, chemically or physically.

Enzymatic fragmentation of the RNA is carried out by nucleases.

Chemical fragmentation of the RNA is carried out by metal cations which may or may not be combined with a
30 chemical catalyst.

In this case, the metal cations are Mg^{++} , Mn^{++} , Cu^{++} , Co^{++} and/or Zn^{++} ions and the chemical catalyst comprises

-12-

imidazole, a substituted analogue, for example N-methylimidazole, or any chemical molecule which has an affinity for the RNA and which carries an imidazole ring or a substituted analogue.

5 Physical fragmentation of the RNA is carried out by sonication or by radiation.

 In all the cases in point, the fixation of the first ligand to the 3' end or the 5' end of an RNA fragment is effected by reacting a molecule R-X, where R
10 comprises the ligand and X is the reactive function, such as a hydroxyl, amine, hydrazine, alkoxylamine, alkyl halide, phenylmethyl halide, iodoacetamide or maleimide. X reacts to the phosphate which is linked to the 2' position, to the 3' position or to the cyclic
15 monophosphate 2'-3' position of the ribose. In a preferred embodiment, X is an alkyl halide, phenylmethyl halide, iodoacetamide or maleimide. In order to facilitate the fixation of the ligand, a linker arm is optionally present between the ligand and the reactive function. In a
20 preferred embodiment, R-X is N-(biotinoyl)-N'-(iodoacetyl)ethylenediamine, (+)-Biotinyl-iodoacetamidyl-3,6-dioxaoctanediamine, N-Iodoacetyl-N-biotinylhexylenediamine, 5-(bromomethyl) fluorescein.

 The present invention also comprises a RNA
25 fragment which is obtained by the above process, . The RNA fragment possesses at the 3' end or the 5' end a single nucleotide which is labeled at the terminal phosphate which was released during fragmentation.

 This RNA fragment comprises from 10 to 150
30 nucleotides, preferably from 30 to 70 nucleotides and preferably from 40 to 60 nucleotides to facilitate hybridization of the RNA fragment to a probe or a target.

-13-

According to a preferred embodiment, the RNA fragment comprises at least one thiophosphate nucleotide.

In addition, the nucleotide bearing the ligand is a thiophosphate nucleotide.

5 According to a preferred embodiment the RNA fragment comprises at the 3' end a phosphate or a thiophosphate bearing a fluorescein bound to an anti-fluorescein antibody bearing at least one biotin, said antibody bound to a labeled streptavidin.

10 The invention relates to the use of an RNA fragment, as defined above, as a probe for detecting an RNA and/or a DNA or an RNA fragment and/or a DNA fragment.

The invention finally relates to the use of an RNA fragment, as defined above, as a labeled target which is
15 able to bind to a capture probe.

Brief description of the drawings :

Figure 1 shows a diagram of the chemical fragmentation of an RNA in the presence of Mn^{++} cations and
20 imidazole.

Figure 2 shows a diagram of a possible mechanism of the fragmentation and labeling of an RNA with a ligand which carries a nucleophilic function.

Figures and examples represent particular
25 embodiments and cannot be regarded as limiting the scope of the present invention.

Example 1 : signal amplification during LDC (labeling during cleavage) with RNA amplicons.

30 1. 1 Preparation of amplicons :

From isolates, one or two freshly grown colonies of bacteria (*Mycobacterium tuberculosis* (ATCC - 27294) on

-14-

Lowenstein-Jensen Medium ; 3- to 5-mm diameter ; ca. 10^8 bacteria) were scraped on the end of a spatula and resuspended into 250 μ l of sterile water in a 1.5 ml Eppendorf Tube. Total nucleic acids were released from culture material by vortexing the bacterial suspension in the presence of glass beads. A 5 μ l aliquot of the lysate was added directly to the PCR. The 16 S hypervariable region was PCR amplified with *Mycobacterium* genus primers (positions 213 to 236 and 394 to 415 on the *M.tuberculosis* reference sequence M20940 [GenBank] ; *M.tuberculosis* amplicon size is 202 bp.). The primers also contained either a bacteriophage T3 or T7 promoter sequence at their 5' ends :

T3-M1, 5'-AATTAACCCTCACTAAAGGGAACACGTGGGTGATCTGCCCTGCA,
and T7-M2, 5'-GTAATACGACTCACTATAGGGCTGTGGCCGGACACCTCTCA.

PCR was carried out in a 100- μ l reaction volume containing 50 mM KCl, 10 mM Tris (pH 8.3), 1.5 mM $MgCl_2$, 0.001% (wt/vol) gelatin, 5% (vol/vol) dimethyl sulfoxide, 0.5 μ M (each) primer, 200 μ M (each) deoxynucleotides triphosphates, and 1.5 U of Taq polymerase (AmpliTaq ; Perkin-Elmer, Norwalk, Conn.). PCR was performed in a Perkin Elmer 2400 thermal cycler with an initial denaturation step at 94°C for 5 min and cycling conditions of 94°C for 45 s, 60°C for 30 s, and 72°C for 30 s for 35 cycles and 72°C for 10 min for the last cycle. PCR product were analyzed by agarose gel electrophoresis.

Promoters-tagged PCR amplicons were used for generating labeled single-stranded RNA targets by in vitro transcription. Each 20- μ l reaction mixture contained approximately 50 ng of PCR product ; 20 U of T3 or T7 RNA polymerase (Promega) ; 40 mM tris acetate (pH 8.1) ; 100 mM $Mg(acetate)_2$; 10 mM dithiothreitol ; 1.25 mM

-15-

ribonucleotides triphosphates (ATP, CTP, GTP, and UTP). The reaction was carried out at 37°C for 1h.

1.2 Labeling during cleavage of amplicons :

RNA amplicons were prepared as described in 1.1.

5 To RNA molecules (1 μ l of reaction mixture), 6 μ l Imidazole (0.1M in pure water), 6 μ l of $MnCl_2$ (1M in pure water) and 2 μ l of 5-(bromomethyl)fluorescein (5-BMF provided by Molecular Probes, Eugene, OR, USA, under reference B1355 ; 100 mM in DMSO) and pure water were
10 added for a final volume of 100 μ l. Reactional medium was homogenized and incubated at 65°C during 30min.

1.3 Protocol for DNA- arrays analysis :

The DNA chip used for analysis of Mycobacteria amplicons is the same as described by A. Troesch et al in
15 J. Clin. Microbiol., 37(1), p 49-55, 1999. Hereby incorporated by reference in its entirety for all purposes. The analysis was performed on the GeneChip® instrument system (reference 900228, Affymetrix, Santa Clara, CA) which comprises the GeneArray® scanner, the
20 GeneChip® hybridization oven, the GeneChip® fluidics station and the GeneChip® analysis software.

1.4 Antibody Staining :

The first step of hybridization, was performed on DNA-arrays using the protocol described in the article
25 incorporated by reference above.

The array was then flushed and a second step of staining was performed using staining solution containing 300 μ l of MES (reference Aldrich 16373-2, 2 M in pure water), 2.4 μ l of Acetylated Bovine Serum Albumin, 6 μ l of Normal Goat
30 IgG, 1.2 μ l of Anti-fluorescein antibody, and pure water for a final volume of 600 μ l.

-16-

Anti-fluorescein, rabbit IgG fraction, biotin-XX conjugate (Ab-antiFbiot), was supplied by Molecular Probes (Eugene, OR. reference A-982)

Acetylated Bovine Serum Albumin (acetylated BSA) solution was supplied by GibcoBRL Life Technologies, (Rockville, MD. reference 15561-020)

Goat IgGReagent Grade was supplied by Sigma Chemical, (St. Louis, MO. reference I-5256)

After 10 minutes of hybridization, the array was flushed, washed with a washing buffer containing 6 X SSPE - Tween 0.01%, and a third step of hybridization was performed, using second staining solution defined as : 300 μ l of MES (2 M in pure Water), 6 μ l of acetylated BSA and 6 μ l of Streptavidin, R-Phycoerythrin conjugate , and pure water for a final volume of 600 μ l.

Streptavidin, R-Phycoerythrin conjugate (SRPhy), was supplied by Molecular Probes (Eugene, OR. Reference S-866)

After 10 minutes of hybridization, the array was flushed and washed using same washing buffer as defined in the second step.

The results in terms of nucleotide base call percentage (BC%), mean signal intensities for probe arrays cells (S expressed in Relative Fluorescence Unit RFU), mean background intensities (B expressed in RFU) and the ratio S/B are generated by functions available on GeneChip® software and are reported in the table below.

Description	BC%	S	B	S/B
Direct labeling with 5-BMF	91.4	9095	4179	2.2
Antibody staining	99.5	17884	2049	8.7

-17-

The data above showed that the signal amplification using antibody staining improves base call percentage and intensity level. The ratio signal versus the background is also improved.

5

Example 2 : Antibody staining of synthesized oligodeoxyribonucleotides as a model for labeling.

2.1. Preparation of oligonucleotide 3'-monothiophosphate.

Oligoribonucleotide (ODN-ps) (5'-CUG AAC GGU AGC
10 AUC UUG AC-3') bearing a monophosphate group at the 3'-end was prepared by Eurogentec (Seraing Belgium) using the phosphoramidite chemistry.

2.2. Labeling during cleavage of oligonucleotide.

Oligoribonucleotide 3'-monothiophosphate was
15 prepared as described in 2.1.

To this oligonucleotide (5 μ l, 1 nmol), 3 μ l Imidazole (0.1M in pure water), 3 μ l of $MnCl_2$ (1M in pure water) and 2 μ l of one of four labels (100 mM) and pure water were added for a final volume of 50 μ l. Reaction
20 medium was homogenized and incubated at 65°C for 30 min.

Different labels were tested :

Label a : N-(biotinoyl)-N'-(iodoacetyl)ethylenediamine (100 mM in DMSO) (Molecular Probe reference B-1591)

Label b : (+)-Biotinyl-iodoacetamidyl-3,6-dioxaoctane
25 diamine (100 mM in pure water) (Pierce, Rockford, IL, reference 21334) iodoacetyl-PEO-biotin.

Label c : N-Iodoacetyl-N-biotinylhexylenediamine (100 mM in DMF) (Pierce, Rockford, IL, reference 21333)

Label d : 5-(bromomethyl)fluorescein (100 mM in DMSO) a
30 control of the detection without signal amplification.

2.3 Hybridization :

-18-

500 μ l of hybridization buffer (1.5ml 20X SSPE + 250ul Triton1% + 3.250ml pure water (6XSSPE 0.05% triton) was then added and this solution was vortexed.

The reaction product was hybridized as described in example 1.

2.4 Antibody staining :

Another step of hybridization was performed on a DNA-checkerboard as described in example 1.4 for the 3 labeling agents bearing a biotin . For label d, analysis was performed directly without the additional step of antibody staining.

This step of staining was performed using staining solution containing 300 μ l of MES (2 M in pure Water), 60 μ l of acetylated BSA, 6 μ l of Streptavidin, R-Phycoerythrin conjugate (SRPhy), and pure water for a final volume of 600 μ l. Acetylated Bovine Serum Albumin (BSA) solution was supplied by GibcoBRL Life Technologies, (Rockville, MD. Reference 15561-020). Streptavidin, R-Phycoerythrin conjugate, was supplied by Molecular Probes (Eugene, OR. Reference S-866)

After 10 minutes of hybridization, the array was flushed and washed using washing buffer 6 X SSPE - Tween 0.01%.

Detection and analysis were performed on DNA-checkerboard array as described in example 1.

This DNA-checkerboard array is designed to analyze the sequence complementary to ODN-ps by a 4-tiling approach as described in WO 9511995.

Analysis :

The results in terms of base call percentage (BC%) intensity levels (S), background (B) and the ratio S/B are reported in the table below :

-19-

Label used	BC%	S	B	S/B
d	92.5	7049	2240	3.2
a	100	41961	1811	23.2
b	100	31301	1510	20.7
c	100	44457	2219	20.0

The signal amplification using a biotin derivative and antibody staining instead of direct labeling with 5-(bromomethyl)fluorescein in the LDC is better in terms of base call percentage and intensity level.

Example 3 : signal amplification during LDC (labeling during cleavage) with natural RNA.

3.1. RNA Isolation :

10 Total RNA was isolated from *Escherichia coli* strain MG1655 grown in LB broth (Teknova). The cells were grown to mid-log phase at 37 °C and harvested by centrifugation. RNA was isolated using the RNeasy kit (Qiagen). The isolated RNA was quantitated by absorbance
15 measurements taken at 260 nm.

3.2. RNA Fragmentation and labeling :

RNA was labeled with fluorescein by combining the following in a final volume of 100 µl: 8 µg of RNA, 30 mM CHES (Aldrich, reference 22403-0), pH 9-9.5, 1 mM 5-(bromomethyl)fluorescein (Molecular Probes, added from a
20 50 mM stock in dimethylformamide), 30 mM manganese chloride. The components were placed in a PCR tube, heated to 65 °C for 40 min and cooled to 4 °C in a GeneAmp PCR

-20-

System 2400 Instrument (Perkin Elmer). To label the RNA with biotin the following were combined in a final volume of 100 μ l: 10 μ g of RNA, 30 mM MOPS (Aldrich reference 16377-5), pH 7.5, 20 mM PEO-iodoacetyl- -biotin (Pierce
5 Rockford, IL, ref : 21334), 10 mM magnesium chloride. The components were placed in a PCR tube, heated to 95 °C for 30 min, then 25 °C for 30 min and cooled to 4 °C in a PCR instrument as above. Labeled RNA fragments were precipitated after the addition of 25 μ g of carrier
10 glycogen. Control RNA spikes (2 femtomoles each) were added to the *E. coli* RNA prior to labeling. The control RNA spikes were produced by *in vitro* transcription of linearized plasmid templates.

3.3. Probe Array Hybridization and Signal Amplification.

15 Hybridizations were performed on an *E. coli* Sense probe array (Affymetrix). The probe array is based on the sequence of *E. coli* K-12 ("The complete genome sequence of *Escherichia coli* K-12", Blattner, F. et al., Science, 277, 1453-1474, 1997, hereby incorporated by reference in its
20 entirety for all purposes). The array contains 15 probe pairs for every RNA or protein-encoding region designated by a b# (Blattner et al., *ibid.*). For these regions, the probe sets are complementary to the native RNA (sense strand). The array also contains probe sets to regions
25 located between the b# regions. These are called intergenic regions. In this case, the probe set represents both orientations of the intergenic regions. In addition the probe array contains probe sets to a number of control sequences. Many of these controls may be spiked into the
30 sample and serve as positive hybridization controls. The cell feature size of the array is (23.5 x 23.5) μ m², and the synthesis area is (12.8 x 12.8) mm².

-21-

The hybridization solution contained 10 µg of fluorescein-labeled RNA fragments or 5 µg of biotin-labeled RNA fragments in a final volume of 200 µl containing 100 mM MES, pH 6.5-7.0, 1 M, Nat 20 mM EDTA, 5 0.01% (v/v) Tween 20, 0.5 nM control oligonucleotide (fluorescein or biotin labeled, matching the RNA sample), 0.1 mg/mL sheared and denatured herring sperm DNA and 0.5 mg/ml acetylated BSA. The hybridization solution was injected directly into the probe array cartridge and 10 hybridized in a GeneChip® Hybridization Oven (Affymetrix, Santa Clara, CA) at 45 °C for 16 hr. Washes and stains were done on the GeneChip® Fluidics Station (Affymetrix). The wash solutions were defined as follows: Stringent Wash Buffer, 100 mM MES, pH 6.5-7.0, 0.1 M Na⁺, 0.01% (v/v) 15 Tween 20; Non-Stringent Wash Buffer, 6X SSPE (from 20X stock, BioWhittaker), 0.01% (v/v) Tween 20, 0.005% (v/v) Antifoam 0-30 (Sigma). For the fluorescein labeled RNA hybridizations, the probe arrays were placed on the Fluidics Station and washed with Non-Stringent Wash Buffer 20 (10 cycles of 2 mixes/cycle at 25°C), followed by Stringent Wash Buffer (4 cycles of 15 mixes/cycle at 50°C) and filled with Non-Stringent Wash Buffer prior to scanning. Fluorescein-labeled probe arrays were scanned on the GeneArray® Scanner (Hewlett Packard) using the 25 following scan parameters: 3 µm pixel, 530 nm wavelength. Following the scan, the fluorescein signal was amplified by mixing the array with 600 µL of 2 µg/mL anti-fluorescein antibody, biotin conjugate (Ab-antiFbiot), 0.1 mg/ml normal goat IgG, and 2 mg/ml acetylated BSA in 100 30 mM MES, pH 6.5-7.0, 1 M Na⁺, 0.05% (v/v) Tween 20 and 0.005% (v/v) Antifoam 0-30 for 10 min at 25°C. The

-22-

antibody binding was followed by staining the array with 600 μ L of 10 μ g/mL streptavidin, R-phycoerythrin (SRPhy) in 100 mM MES, pH 6.5-7.0, 1 M Na⁺, 0.05% (v/v) Tween 20, 0.005% (v/v) Antifoam 0-30 and 5 mg/ml acetylated BSA for 10 min at 25°C. Following the streptavidin phycoerythrin stain, the array was washed with Non-Stringent Hybridization Buffer (10 cycles of 4 mixes/cycle at 30°C). The array was scanned using the 3 μ m pixel and 570 nm wavelength parameters. For biotin-labeled RNA hybridizations the probe arrays were washed with Non-Stringent Wash Buffer (10 cycles of 2 mixes/cycle at 25°C), followed by Stringent Wash Buffer (4 cycles of 15 mixes/cycle at 50°C) as described above. The array was then stained with streptavidin phycoerythrin as described above followed by a wash with Non-Stringent Wash Buffer (10 cycles of 4 mixes/cycle at 25°C). The signal on the array was then amplified by mixing the array with 600 μ L of 3 μ g/ml anti-streptavidin antibody (goat), biotinylated (Vector Laboratories), 0.1 mg/ml normal goat IgG, and 2 mg/ml acetylated BSA in 100 mM MES, pH 6.5-7.0, 1 M Na⁺, 0.05% (v/v) Tween 20 and 0.005% (v/v) Antifoam 0-30 for 10 min at 25°C. The array was stained again with streptavidin phycoerythrin as described above followed by a wash with Non-Stringent Wash Buffer (15 cycles of 4 mixes/cycle at 30°C). All of the steps were handled sequentially on the GeneChip® Fluidics Station. The array was then scanned using the 3 μ m pixel and 570 nm wavelength parameters.

3.4. Data Analysis :

The scan data was analyzed by GeneChip® Software (version 3.1, Affymetrix). Data was produced by using the Expression Analysis Algorithm set at default parameters.

-23-

The present calls were selected from the coding sequences (stable RNA's and open reading frames) on the array. The Average Difference was defined as the intensity difference between the perfect match probe and the mismatch probe averaged over the 16 probe pairs used to define a coding sequence.

3.5. Results :

The results of the hybridizations are summarized in the following two tables.

10

Table 1. Total E. coli RNA Comparison

	Fluorescein Label		Biotin Label
	No Amplification	Antibody Amplification	
Present Calls	826	1199	737
% Present Calls	19%	28%	17%
Total Coding Sequences	4331	4331	4331
Mean Avg. Difference	6	180	147

Table 1 summarizes the results obtained from the coding sequences on the array. The value of the antibody amplification on fluorescein labeled target is clearly seen by comparing the number of present calls and the mean average difference values. In this case the additional signal generated by the antibody amplification increased

15

-24-

the number of present calls from 826 to 1199 and increased the mean average difference from 6 to 180. The antibody amplification of biotin-labeled RNA produced mean average difference signals that are similar but slightly lower than those obtained with amplification of the fluorescein label. It should be noted the biotin-labeled sample was one-half the amount of the fluorescein-labeled sample.

Table 2. Control RNA Spike Comparison

	Fluorescein Label				Biotin Label	
	No Amplification		Antibody Amplification			
Probe Set	Avg Diff ¹ .	Abs. Call ²	Avg Diff ¹ .	Abs. Call ²	Avg Diff ¹ .	Abs. Call ²
DapX-5	11	P	192	P	1237	P
DapX-M	0	A	111	P	507	P
DapX-3	7	P	218	P	1554	P
LysX-5	12	P	417	P	1795	P
LysX-M	3	A	150	P	702	P
LysX-3	3	P	154	P	384	P
PheX-5	8	P	340	P	197	P
PheX-M	6	P	162	P	297	P
PheX-3	5	A	358	P	1474	P
ThrX-5	10	P	234	P	123	P
ThrX-M	9	P	144	P	196	P
ThrX-3	6	M	233	P	337	P

10 ¹ Average Difference

² Absolute Call, P = Present, A = Absent, M = Marginal

-25-

Table 2 summarizes data obtained with RNA control spikes. With the fluorescein-labeled spikes the antibody signal amplification greatly improved the mean average difference values converting any absent or marginal call into a present call. The biotin-labeled RNA spikes produced higher signals in 10 out of 12 probe sets when compared to the fluorescein-labeled spikes after antibody signal amplification.

-26-

CLAIMS

1. Process for labeling with signal amplification a ribonucleic acid (RNA), characterized in that it
5 comprises :

- fragmenting the RNA,
- fixing a first ligand to the terminal phosphate which is located at the 3' end and/or the 5' end of each fragment of said RNA, said terminal phosphate having been
10 released during the fragmentation, and
- binding a labeling agent to said first ligand.

2. Process according to claim 1, wherein the binding of the labeling agent to said first ligand is effected indirectly.

15 3. Process according to claim 2, wherein the first ligand is bound to a first antiligand, said first antiligand is bound to a second ligand and the labeling agent is a second antiligand bearing at least one label and able to react with said second ligand.

20 4. Process according to claim 3, wherein first ligand / first antiligand and second ligand / second antiligand combinations are selected in the group consisting of biotin/ streptavidin, hapten/antibody, antigen/antibody, peptide/antibody, sugar/lectin and
25 polynucleotide/ complementary polynucleotide.

5. Process according to claim 4, wherein the first and second ligands are the same.

6. Process according to claim 4, wherein the first and second ligands are different.

30 7. Process according to claim 6, wherein the first ligand is a derivative of fluorescein and the second ligand is a derivative of biotin.

-27-

8. Process according to any one of claims 1 to 3, wherein the first ligand is a derivative of biotin and the labeling agent or the first antiligand is a derivative of streptavidin.

5 9. Process according to claim 1 or 2, wherein the fragmentation and the fixation are effected in one step.

10 10. Process according to claim 1 or 2, wherein the fragmentation and the fixation are effected in two steps.

11. Process according to claim 1, wherein the
10 binding of the labeling agent to the first ligand is covalent.

12. Process according to claim 1, wherein the binding of the labeling agent to the first ligand is non covalent.

15 13. Process according to any one of claims 1 to 12, wherein the fixation of the first ligand to the 3' end or the 5' end of an RNA fragment is effected by reacting a reactive function, which is carried by said first ligand, to the phosphate which is in the 2' position, in the 3' position or in the cyclic monophosphate 2'-3' position, with respect to the ribose.

20 14. Process according to anyone of claims 1 to 13, wherein the fragmentation and/or the fixation of the first ligand to the 3' end or the 5' end of an RNA fragment is effected by reacting a nucleophilic, electrophilic or halide function which is carried by said first ligand to the phosphate in the 2' position, in the 3' position or in the cyclic monophosphate 2'-3' position, with respect to the ribose.

30 15. Process according to anyone of claims 1 to 13, wherein the fragmentation of the RNA is effected enzymatically, chemically or physically.

-28-

16. Process according to claim 15, wherein the enzymatic fragmentation of the RNA is carried out by means of nucleases.

17. Process according to claim 15, wherein the
5 chemical fragmentation of the RNA is carried out by means of metal cations which may or may not be combined with a chemical catalyst.

18. Process according to claim 17, wherein the metal cations are Mg^{++} , Mn^{++} , Cu^{++} , Co^{++} and/or Zn^{++} ions, and
10 in that the chemical catalyst consists of imidazole, a substituted analogue, for example N-methylimidazole, or any chemical molecule which has an affinity for the RNA and which carries an imidazole nucleus or a substituted analogue.

15 19. Process according to claim 15, wherein the physical fragmentation of the RNA is carried out by means of sonication or by means of radiation.

20. Process according to anyone of claims 1 to 19, wherein the fixation of the first ligand to the 3' end or
20 the 5' end of an RNA fragment is effected by reacting a molecule R-X to the phosphate which is linked to the 2' position, to the 3' position or to the cyclic monophosphate 2'-3' position of the ribose, where R consists of the first ligand and X is the reactive
25 function, selected from the group consisting of hydroxyl, amine, hydrazine, alkoxylamine, alkyl halide, phenylmethyl halide, iodoacetamide or maleimide.

21. Process according to claim 20, wherein R-X is selected from the group consisting of 5-(bromofluorescein)
30 and derivatives of iodoacetyl biotin.

22. RNA fragment which is obtained by the process according to anyone of claims 1 to 21, wherein the RNA

-29-

fragment comprises at the 3' end or the 5' end a single nucleotide which is labeled at the terminal phosphate released during the fragmentation.

23. RNA fragment according to claim 22, wherein it
5 comprises from 10 to 150 nucleotides.

24. RNA fragment according to either one of claims 22 and 23, wherein the RNA fragment comprises at least one thiophosphate nucleotide, bearing a biotin bound to streptavidine antibody against.

10 25. RNA fragment according to claim 24, wherein the nucleotide bearing the ligand is a thiophosphate nucleotide.

26. RNA fragment comprising at 3' end a phosphate or a thiophosphate bearing a fluorescein bound to an anti-
15 fluorescein antibody bearing at least one biotin, said antibody bound to a labeled streptavidin.

27. Use of an RNA fragment according to any one of claims 22 to 26 as a probe for detecting an RNA and/or a DNA or an RNA fragment and/or a DNA fragment.

20 28. Use of an RNA fragment according to any one of claims 22 to 26 as a labeled target which is able to bind to a capture probe.

Fig. 1





Fig. 2

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/02072

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 27229 A (UNIV CHICAGO) 25 June 1998 (1998-06-25) the whole document ---	1-4, 7, 11-13, 15-19, 22, 23, 27
Y	US 5 317 098 A (MILLAR SHARON L ET AL) 31 May 1994 (1994-05-31) cited in the application the whole document ---	1-4, 7, 11-13, 22
Y	WO 94 29723 A (BIO MERIEUX ; CROS PHILIPPE (FR); KURFURST ROBIN (FR); BATAIL NICO) 22 December 1994 (1994-12-22) cited in the application * see especially claims 20-30 * the whole document --- -/--	1-4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

24 October 2000

Date of mailing of the international search report

30/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Knehr, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 99/02072

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 88 04300 A (UNIVERSITY PATENTS INC) 16 June 1988 (1988-06-16) cited in the application the whole document ---	1, 15, 16, 22, 23, 27
Y	WO 93 20241 A (ABBOTT LAB) 14 October 1993 (1993-10-14) the whole document ---	1, 15, 17, 18
Y	EP 0 801 072 A (BOEHRINGER MANNHEIM GMBH) 15 October 1997 (1997-10-15) the whole document ---	1, 15, 19
A	WO 95 08000 A (BIO MERIEUX ; CROS PHILIPPE (FR); DELAIR THIERRY (FR); CHARLES MARI) 23 March 1995 (1995-03-23) cited in the application the whole document ---	
A	DE 39 10 151 A (SELIGER HARTMUT PROF DR ; LINDL TONI DR (DE); JIRIKOWSKY GUSTAV DR) 4 October 1990 (1990-10-04) the whole document ---	
P, X	WO 99 65926 A (BIO MERIEUX ; LAAYOUN ALI (FR)) 23 December 1999 (1999-12-23) the whole document -----	1-28

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/18 99/02072

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9827229 A	25-06-1998	US 5905024 A AU 5898998 A EP 1007731 A	18-05-1999 15-07-1998 14-06-2000
US 5317098 A	31-05-1994	NONE	
WO 9429723 A	22-12-1994	FR 2706618 A AT 179799 T CA 2142186 A DE 69418284 D DE 69418284 T EP 0655136 A ES 2131690 T US 5849480 A	23-12-1994 15-05-1999 22-12-1994 10-06-1999 09-12-1999 31-05-1995 01-08-1999 15-12-1998
WO 8804300 A	16-06-1988	US 4987071 A AT 129251 T DE 3751567 D DE 3751567 T EP 0291533 A HK 188395 A JP 2530906 B JP 1501445 T MX 9203713 A US 5591610 A US 5037746 A US 5116742 A US 5093246 A US 6025167 A US 5354855 A	22-01-1991 15-11-1995 23-11-1995 02-05-1996 23-11-1988 22-12-1995 04-09-1996 25-05-1989 01-07-1992 07-01-1997 06-08-1991 26-05-1992 03-03-1992 15-02-2000 11-10-1994
WO 9320241 A	14-10-1993	US 5858650 A AU 4026593 A EP 0646180 A JP 7505298 T	12-01-1999 08-11-1993 05-04-1995 15-06-1995
EP 0801072 A	15-10-1997	US 5834198 A JP 10070985 A	10-11-1998 17-03-1998
WO 9508000 A	23-03-1995	FR 2710075 A AT 186330 T CA 2149315 A DE 69421514 D DE 69421514 T EP 0669991 A ES 2140560 T US 5695936 A US 6017707 A	24-03-1995 15-11-1999 23-03-1995 09-12-1999 06-07-2000 06-09-1995 01-03-2000 09-12-1997 25-01-2000
DE 3910151 A	04-10-1990	NONE	
WO 9965926 A	23-12-1999	FR 2780059 A AU 4269299 A	24-12-1999 05-01-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.